Metabolism of rifabutin in human enterocyte and liver microsomes: Kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents

Clinical Pharmacology and Therapeutics

Volumn 61, Issue 5, 1997, Pages 554-562

  Iatsimirskaia, Eugenia ^a   Tulebaev, Samir ^a   Storozhuk, Elena ^a   Utkin, Ilya ^a   Smith, Douglas ^a   Gerber, Nicholas ^a   Koudriakova, Tatiana ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; AZITHROMYCIN; CHOLINESTERASE; CLARITHROMYCIN; CYTOCHROME P450; DRUG METABOLITE; DRUG METABOLIZING ENZYME; FLUCONAZOLE; KETOCONAZOLE; MACROLIDE; O DEMETHYLASE; RIFABUTIN;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; DEACETYLATION; DRUG METABOLISM; DRUG TRANSFORMATION; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTESTINE CELL; LIVER MICROSOME METABOLISM; LYMPHOBLASTOID CELL; MALE; MICHAELIS CONSTANT; PRIORITY JOURNAL; TUBERCULOSIS;

ACETYLATION; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTIFUNGAL AGENTS; CELL SEPARATION; CHOLINESTERASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONIC NEOPLASMS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; INTESTINAL MUCOSA; MACROLIDES; METHYLATION; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; RIFABUTIN;

EID: 0030903839     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90135-1     Document Type: Article

References (46)

1. Skinner MH, Hsieh M, Torseth J, Pauloin D, Bhatia G, Harkonen S, et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 1989;33:1237-41.
2. Strolin Benedetti M, Efthymiopoulos C, Sassella D, Moro E, Repetto M. Autoinduction of rifabutin metabolism in man. Xenobiotica 1990;20:1113-9.
3. 14C-rifabutin in animals and man. J Antimicrob Chemother 1990;26:813-22.
4. Cocchiara G, Strolin Benedetti M, Vicario GP, Ballabio M, Gioia B, Vioglio S, et al. Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers. Xenobiotica 1989;19:769-80.
5. Vigevani A, Ballabio M, Gioia B, Marsili L, Vioglio S, Franceschi G. Identification of urinary metabolites of rifamycin LM 427 in man. J Antibiot (Tokyo) 1985; 38:1799-802.
6. Utkin IB, Koudriakova T, Iatsimirskaia E, Thompson T, Vouros P, Gerber N. Metabolism of rifabutin in the rat [abstract]. XI International Conference of AIDS, Vancouver, Canada, July 7-12, 1996:123.
7. Koudriakova T, Iatsimirskaia E, Tulebaev S, Spetie D, Utkin I, Mullet D, et al. In vivo disposition and metabolism by liver and enterocyte microsomes of the anti-tubercular drug rifabutin in the rat. J Pharmacol Exp Ther 1996;279:1300-9.
8. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6β-hydroxylase cytochrome P450 enzyme. Arch Biochem Biophys 1988;263:424-31.
9. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J Clin Invest 1989;83:688-97.
10. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interaction of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43:630-5.
11. Kumar GN, Walle UK, Walle T. Cytochrome P450 3A-mediated human liver microsomal taxol 6α-hydroxylation. J Pharmacol Exp Ther 1994;268:1160-5.
12. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996;277:423-31.
13. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029-36.
14. Christians U, Sewing KF. Cyclosporin metabolism in transplant patients. Pharmacol Ther 1993;57:291-345.
15. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502.
16. Zhou-Pan XR, Seree E, Zhou XJ, Placidi M, Maurel P, Barra Y, et al. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993;53:5121-6.
17. Jurima-Romet M, Crawford K, Cyr T, Inaba T. Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994;22:849-57.
18. Back DJ, Tjia JF, Abel SM. Azoles, allylamines and drug metabolism. Br J Dermatol 1992;126:14-8.
19. Gupta SK, Bakran A, Johnson RW, Rowland M. Cyclosporine-erythromycin interaction in renal transplant patients. Br J Clin Pharmacol 1989;27:475-81.
20. Saran BR, Maguire AM, Nichols C, Frank I, Hertle RW, Brucker AJ, et al. Hypopyon uveitis in patients with acquired immunodeficiency syndrome treated for systemic Mycobacterium avium complex infection with rifabutin. Arch Ophthalmol 1994;112:1159-65.
21. Tseng AL, Walmsley SL. Rifabutin-associated uveitis. Ann Pharmacother 1995;29:1149-55.
22. The Datri 001 Study Group. Coadministration of clarithromycin (CL) alters the concentration-time profile of rifabutin (RFB). [abstract]. 34th International Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4-7, 1994:3.
23. Trapnell CB, Narang PK, Lavelle JP. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med 1996;124:573-6.
24. Narang PK, Trapnell CB, Schoenfelder JR, Lavelle JP, Bianchine JR. Fluconazole and enhanced effect of rifabutin prophylaxis. N Engl J Med 1994;330:1316-7.
25. Gonzalez FJ. In vitro systems for prediction of rates of drug clearance and drug interactions. Anesthesiology 1992;77:413-5.
26. Vickers AE, Meyer E, Dannecker R, Keller B, Tynes RE, Maurer G. Human liver cytochrome P450 3A biotransformation of cyclosporin derivative SDZ IMM125. Drug Metab Dispos 1995;23:321-6.
27. Jamis-Dow CA, Klecker RW, Katki AG, Collins JM. Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 1995;36:107-14.
28. Lampen A, Christians U, Bader A, Hackbarth I, Sewing KF. Drug interactions and interindividual variability of cyclosporin metabolism in the small intestine. Pharmacology 1996;52:159-68.
29. Fontana E, Giarda S, Vioglio S, Vicario GP. Synthesis of carbon-14 labelled spiro-piperidyl-rifamycins (LM 118) and rifabutin (LM 427). J Labeled Compounds Radiopharm 1987;24:1337-49.
30. Marsili L, Pasqualucci CR, Vigevani A, Gioia B, Schioppacassi G, Oronzo G. New rifamycins modified at position 3 and 4: synthesis, structure and biological evaluation. J Antibiot (Tokyo) 1981;34:1033-8.
31. Mason EE, Printen KJ, Blommers TJ, Lewis JW, Scott DH. Gastric bypass in morbid obesity. Am J Clin Nutr 1980;33:395-405.
32. Mason EE. Vertical banded gastroplasty for obesity. Arch Surg 1982;117:701-6.
33. Bonkovsky HL, Hauri HP, Marti U, Gasser R, Meyer UA. Cytochrome P-450 of small intestinal epithelial cells. Gastroenterology 1985;88:458-67.
34. Eadie GS. The inhibition of cholinesterase by physostigmine and prostigmine. J Biol Chem 1942;146:85-93.
35. Hofstee BHJ. Non-inverted versus inverted plots in enzyme kinetics. Nature 1959;184:1296-7.
36. Dixon M. The determination of enzyme inhibitor constants. Biochem J 1953;55:170-1.
37. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951;193:265-75.
38. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes; I: evidence for its hemoprotein nature. J Biol Chem 1964;239:2370-8.
39. Lown KS, Kolars JC, Thummel KE, Barnett JK, Kunze KL, Wrighton SA, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Drug Metab Dispos 1994;22:947-52.
40. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. J Biol Chem 1989;264:10388-95.
41. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60:14-24.
42. Williams FM. Clinical significance of esterases in man. Clin Pharmacokinet 1985;10:392-403.
43. Chu S, Wilson DS, Guay DRP, Craft C. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J Clin Pharmacol 1992;32:1045-9.
44. Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993;24: 10-27.
45. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988; 14:13-34.
46. Badcock NR, Bartholomeusz FD, Frewin DB, Sansom LN, Reid JG. The pharmacokinetics of ketoconazole after chronic administration in adults. Eur J Clin Pharmacol 1987;33:531-4.